Table 3.
Selected toxicity data from randomized studies with mandated crossover in the monotherapy arm (% grade ≥3)*
| First author, year (ref) | Comparison (No. of cycles if preplanned) | Febrile neutropenia, % | Mucositis, % | Diarrhea, % | Neurotoxicity, % |
| Alba, 2004 (27) | A × 3 → Doc × 3 | 29 | 12 | 3 | 4 |
| A + Doc × 6 | 48 | 7 | 10 | 4 | |
| Beslija, 2006 (43) | Doc → X | 12 | 6 | 6 | NR |
| Doc + X | 11 | 15 | 11 | NR | |
| Conte, 2004 (22) | E × 4 → Pac × 4 | 6 | 4 | NR | 13 |
| E + Pac × 8 | 7 | 8 | NR | 4 | |
| Koroleva, 2001 (28) | Doc × 4 → A × 4 | 10 | 7 | 2 | 5 |
| A + Doc* × 8 | 15 | 0 | 10 | 2 | |
| A + Doc† × 8 | 10 | 2 | 3 | 0 | |
| Sjöstrom, 1999 (39) | Doc → MF | 26† | 9 | 10 | 5 |
| MF → Doc | 6† | 5 | 10 | 1 | |
| Sledge, 2003 (21) | A → Pac | 4† | 8 | 2 | 2 |
| Pac → A | 8† | 3 | 2 | 4 | |
| A + Pac | 13† | 4 | 4 | 11 | |
| Soto, 2006 (44) | X → Pac or Doc | NR | 6 | 5 | NR |
| X + Pac | NR | 3 | 7 | NR | |
| X + Doc | NR | 4 | 7 | NR | |
| Tomova, 2008 (47) | Doc × 4→ G × 4 | 10 | 2 | 0 | NR |
| Doc + G × 8 | 4 | 4 | 4 | NR |
*
A = doxorubicin; A + Doc* = doxorubicin 50 mg/m2 and docetaxel 75 mg/m2; A + Doc† = doxorubicin 60 mg/m2 and docetaxel 60 mg/m2; Doc = docetaxel; E = epirubicin; G = gemcitabine; MF = methotrexate-5-fluorouracil; NR = not reported; Pac = paclitaxel; X = capecitabine.
†
Infection including febrile neutropenia.